Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 733

1.

Honey for acute cough in children.

Oduwole O, Udoh EE, Oyo-Ita A, Meremikwu MM.

Cochrane Database Syst Rev. 2018 Apr 10;4:CD007094. doi: 10.1002/14651858.CD007094.pub5. Review.

PMID:
29633783
2.

Chondroprotective Effects and Mechanisms of Dextromethorphan: Repurposing Antitussive Medication for Osteoarthritis Treatment.

Chen LW, Liu FC, Hung LF, Huang CY, Lien SB, Lin LC, Lai JH, Ho LJ.

Int J Mol Sci. 2018 Mar 12;19(3). pii: E825. doi: 10.3390/ijms19030825.

3.

Internet pseudoscience: Testing opioid containing formulations with tampering potential.

Pascali JP, Fais P, Vaiano F, Pigaiani N, D'Errico S, Furlanetto S, Palumbo D, Bertol E.

J Pharm Biomed Anal. 2018 May 10;153:16-21. doi: 10.1016/j.jpba.2018.02.014. Epub 2018 Feb 10.

PMID:
29455092
4.

Randomized open-label trial of dextromethorphan in Rett syndrome.

Smith-Hicks CL, Gupta S, Ewen JB, Hong M, Kratz L, Kelley R, Tierney E, Vaurio R, Bibat G, Sanyal A, Yenokyan G, Brereton N, Johnston MV, Naidu S.

Neurology. 2017 Oct 17;89(16):1684-1690. doi: 10.1212/WNL.0000000000004515. Epub 2017 Sep 20.

PMID:
28931647
5.

Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice.

Nguyen L, Scandinaro AL, Matsumoto RR.

Pharmacol Biochem Behav. 2017 Oct;161:30-37. doi: 10.1016/j.pbb.2017.09.005. Epub 2017 Sep 12.

PMID:
28916283
6.

MK-801, but not naloxone, attenuates high-dose dextromethorphan-induced convulsive behavior: Possible involvement of the GluN2B receptor.

Tran HQ, Chung YH, Shin EJ, Tran TV, Jeong JH, Jang CG, Nah SY, Yamada K, Nabeshima T, Kim HC.

Toxicol Appl Pharmacol. 2017 Nov 1;334:158-166. doi: 10.1016/j.taap.2017.09.010. Epub 2017 Sep 13.

PMID:
28916251
7.

The Effect of Dextromethorphan Premedication on Cough and Patient Tolerance During Flexible Bronchoscopy: A Randomized, Double-blind, Placebo-controlled Trial.

Amini S, Peiman S, Khatuni M, Ghalamkari M, Rahimi B.

J Bronchology Interv Pulmonol. 2017 Oct;24(4):263-267. doi: 10.1097/LBR.0000000000000385.

PMID:
28891835
8.

You Abused What? Getting High with Unique Medications.

Heeren N, Farver D.

S D Med. 2017 Jan;70(1):38-39. No abstract available.

PMID:
28810101
9.

Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.

Allen C, Zarowitz B, O'Shea T, Peterson E, Yonan C, Waterman F.

Geriatr Nurs. 2018 Jan - Feb;39(1):54-59. doi: 10.1016/j.gerinurse.2017.06.002. Epub 2017 Aug 12.

PMID:
28807457
10.

Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Adedeji WA, Igbinoba SI, Fakeye TO, Oladosu IA, Fehintola FA, Ma Q, Morse GD.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1145-1152. doi: 10.1080/17512433.2017.1362979. Epub 2017 Aug 30.

PMID:
28786716
11.

Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan.

Dy P, Arcega V, Ghali W, Wolfe W.

BMJ Case Rep. 2017 Aug 7;2017. pii: bcr-2017-221486. doi: 10.1136/bcr-2017-221486.

PMID:
28784915
12.

EEG with extreme delta brush in young female with methotrexate neurotoxicity supports NMDA receptor involvement.

Schmidt LS, Kjær TW, Schmiegelow K, Born AP.

Eur J Paediatr Neurol. 2017 Sep;21(5):795-797. doi: 10.1016/j.ejpn.2017.05.008. Epub 2017 Jun 15.

PMID:
28655493
13.

Pharmacological Manipulation of Cortical Inhibition in the Dorsolateral Prefrontal Cortex.

Salavati B, Rajji TK, Zomorrodi R, Blumberger DM, Chen R, Pollock BG, Daskalakis ZJ.

Neuropsychopharmacology. 2018 Jan;43(2):354-361. doi: 10.1038/npp.2017.104. Epub 2017 May 29.

PMID:
28553835
14.

Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.

Murrough JW, Wade E, Sayed S, Ahle G, Kiraly DD, Welch A, Collins KA, Soleimani L, Iosifescu DV, Charney DS.

J Affect Disord. 2017 Aug 15;218:277-283. doi: 10.1016/j.jad.2017.04.072. Epub 2017 Apr 29.

PMID:
28478356
15.

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.

Mov Disord. 2017 Jun;32(6):893-903. doi: 10.1002/mds.26976. Epub 2017 Mar 30.

PMID:
28370447
16.

In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report.

Gaedigk A, Twist GP, Farrow EG, Lowry JA, Soden SE, Miller NA.

Pharmacogenomics. 2017 Apr;18(5):427-431. doi: 10.2217/pgs-2016-0192. Epub 2017 Mar 14.

17.

A Stroke Mimic: Methotrexate-induced Neurotoxicity in the Emergency Department.

Rogers P, Pan WJ, Drachtman RA, Haines C.

J Emerg Med. 2017 Apr;52(4):559-561. doi: 10.1016/j.jemermed.2016.11.016. Epub 2017 Jan 13.

PMID:
28094079
18.

Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.

Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, Yu H, Wymer J, Cudkowicz M, Macklin EA, Schoenfeld D, Pattee G.

Neurotherapeutics. 2017 Jul;14(3):762-772. doi: 10.1007/s13311-016-0508-5. Erratum in: Neurotherapeutics. 2017 Mar 10;:.

19.

Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?

Magalhães P, De Andrés F, Falcão A, LLerena A, Alves G.

J Pharm Pharm Sci. 2016 Oct - Dec;19(4):520-529. doi: 10.18433/J3D313.

20.

Recognizing and treating pseudobulbar affect.

Sauvé WM.

CNS Spectr. 2016 Dec;21(S1):34-44. doi: 10.1017/S1092852916000791. Review.

PMID:
28044945

Supplemental Content

Loading ...
Support Center